Icosavax_Logo.jpg
Icosavax Reports Third Quarter 2023 Financial Results and Provides Corporate Update
14 nov. 2023 16h05 HE | Icosavax, Inc.
- Reported positive twelve-month durability data and initial proof-of-concept for revaccination with IVX-121 against RSV - - IVX-A12 (RSV+hMPV) Phase 2 topline interim data expected by end of 2023...
GeoVax.png
Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023
14 nov. 2023 09h00 HE | GeoVax, Inc.
Single-Dose Protection Demonstrated Against Multiple SARS-CoV-2 Variants ATLANTA, GA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company...
TIP_link_300x300.jpg
Immunoassay Market Revenue to Cross $37.98 Billion, Globally, by 2027 - Exclusive Report by The Insight Partners
23 oct. 2023 10h43 HE | The Insight Partners
Pune, India, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Immunoassays (IAs) are bio analytical technique in which the quantitation of the analyte relies on the reaction of an antigen and an antibody....
VIR_logo_large_color.jpg
Vir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats
03 oct. 2023 07h59 HE | Vir Biotechnology, Inc.
Vir Biotechnology Awarded approximately $50 million in BARDA Funding to Support Development of Antibody Platform Technologies for COVID-19
190705_Biontech_Logo_RGB_Dark Green (Preferred)_0.png
Pfizer and BioNTech Receive Health Canada Authorization for XBB.1.5-Adapted Monovalent COVID-19 Vaccine
28 sept. 2023 12h24 HE | BioNTech SE
COMIRNATY Omicron XBB.1.5-adapted monovalent COVID-19 vaccine is now authorized in Canada for individuals 6 months of age and olderNew Omicron XBB.1.5-adapted COVID-19 vaccine is administered as a...
GeoVax.png
GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference
20 sept. 2023 09h00 HE | GeoVax, Inc.
Preclinical Data for GEO-CM02 Demonstrates Single-Dose ProtectionAgainst Multiple SARS-CoV-2 Variants ATLANTA, GA, Sept. 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq:...
GeoVax.png
GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients
19 sept. 2023 09h00 HE | GeoVax, Inc.
Data Published From Phase 2 Open-Label Study of GEO-CM04S1 ATLANTA, GA, Sept. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing...
logo.png
Bioxytran Announces Broad Spectrum Antiviral Activity Highlighted in ProLectin-M
14 sept. 2023 09h41 HE | BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, Sept. 14, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral...
Pfizer und BioNTech
Pfizer und BioNTech erhalten positive CHMP-Empfehlung für an Omikron XBB.1.5 angepassten COVID-19-Impfstoff in der Europäischen Union
30 août 2023 10h00 HE | BioNTech SE
Der aktualisierte COVID-19-Impfstoff ist auf die Omikron XBB.1.5-Sublinie von SARS-CoV-2 zugeschnitten und wird für Personen ab 6 Monaten empfohlenDie Beurteilung basiert auf präklinischen Daten, die...
Pfizer and BioNTech
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union
30 août 2023 10h00 HE | BioNTech SE
The updated COVID-19 vaccine is tailored to the Omicron XBB.1.5 sublineage of SARS-CoV-2 and is recommended for individuals 6 months of age and olderRecommendation is based on pre-clinical data...